MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
04. März 2019 08:02 ET
|
MyoKardia, Inc.
Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers...
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
26. Juni 2018 08:30 ET
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
21. Mai 2018 07:30 ET
|
MyoKardia, Inc.
Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements Expected to Initiate in Second...
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
08. März 2018 16:02 ET
|
MyoKardia, Inc.
Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance Study Results Inform Phase 3 EXPLORER-HCM Dosing; First Patient Planned for Q2 2018 Conference Call Today...